Takeda Pharmaceutical Co Ltd (TAK) Stock Analysis and Metrics

Takeda Pharmaceutical

NYSE: TAK

$17.25 ▲ +0.43 (+2.59%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap27.18 Bn

P/E-10.29

P/S0.59

Div. Yield0.07

ROIC (Qtr)0.00

Total Debt (Qtr)28.76 Bn

Revenue Growth (1y) (Qtr)-11.85

Add ratio to table…

About

Takeda Pharmaceutical Company Limited is a global R&D-driven biopharmaceutical company engaged in the research, development, production, and global commercialization of pharmaceutical products. The company focuses on delivering innovative, life-transforming medicines by advancing treatment options for high unmet medical needs in both rare and prevalent conditions. Takeda operates in approximately 80 countries and regions with major research centers in Japan and the United States, and a significant commercial presence in the United States, Japan, Europe, and a growing business in China.

Takeda generates revenue primarily through the sale of its pharmaceutical products across six key business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience. Revenue is derived from the commercialization of branded prescription drugs such as ENTYVIO for inflammatory bowel disease, TAKHZYRO for hereditary angioedema, GAMMAGARD LIQUID/KIOVIG for immunodeficiency disorders, ALUNBRIG for non-small cell lung cancer, VYVANSE/ELVANSE for attention deficit hyperactivity disorder, and QDENGA for dengue prevention. The company serves patients, healthcare providers, and health systems worldwide through its global sales and marketing infrastructure.

The company operates through the following segments: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience.

• Gastroenterology focuses on the research, development, and commercialization of treatments for gastrointestinal diseases such as ulcerative colitis, Crohn’s disease, eosinophilic esophagitis, and short bowel syndrome, with key products including ENTYVIO, EOHILIA, TAKECAB/VOCINTI, and GATTEX/REVESTIVE.

• Rare Diseases encompasses therapies for hereditary angioedema, post-transplant cytomegalovirus infection, congenital thrombotic thrombocytopenic purpura, Hunter syndrome, Fabry disease, and hemophilia A, with principal products such as TAKHZYRO, LIVTENCITY, ADZYNMA, ELAPRASE, REPLAGAL, ADVATE, and ADYNOVATE/ADYNOVI.

• Plasma-Derived Therapies involves the collection, manufacturing, and commercialization of immunoglobulin and albumin products derived from human plasma, including GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, FLEXBUMIN, and Human Albumin, used to treat immunodeficiency disorders, neurological conditions, and volume depletion.

• Oncology develops and markets treatments for hematologic malignancies, solid tumors, and hormone-responsive cancers, featuring products like ALUNBRIG, FRUZAQLA, LEUPLIN/ENANTONE, NINLARO, ADCETRIS, and ICLUSIG for conditions including non-small cell lung cancer, metastatic colorectal cancer, prostate and breast cancer, multiple myeloma, Hodgkin lymphoma, and chronic myeloid leukemia.

• Vaccines focuses on the prevention of infectious diseases through vaccine development, with QDENGA as its principal product designed to protect against dengue fever in individuals aged four and older.

• Neuroscience develops treatments for neurological and psychiatric disorders such as attention deficit hyperactivity disorder, binge eating disorder, and major depressive disorder, with key products including VYVANSE/ELVANSE and TRINTELLIX.

Takeda holds a leading position in several therapeutic areas, particularly in gastroenterology with ENTYVIO as a top-selling product globally, and in rare diseases with TAKHZYRO and immunoglobulin therapies. The company competes with large biopharmaceutical firms such as Pfizer, Merck, Roche, AbbVie, and Bristol-Myers Squibb, as well as specialty players in niche markets. Its competitive advantages stem from a diversified portfolio, strong R&D pipeline, global manufacturing and plasma collection network, and strategic partnerships that enhance innovation and market reach.

Takeda serves a diverse customer base including hospitals, clinics, physicians, patients, and healthcare systems across the globe. The company’s products are used in outpatient and inpatient settings for chronic and acute conditions, with specific therapies administered in specialty care centers, infusion clinics, and retail pharmacies depending on the formulation and indication.

Investment Thesis

▲ Bull case

Takeda's strategic partnership with Innovent Biologics represents a transformative catalyst that the market is underestimating, as it adds three differentiated oncology assets with global rights outside Greater China and an initial addressable market exceeding $48 billion, positioning the company to become a leader in solid tumor treatment where it previously had minimal presence; the collaboration leverages cost-sharing arrangements like the 60-40 split for IBI363 and Blackstone partnership for mezagitamab to manage R&D expenses while advancing late-stage pipeline candidates, with U.S.-based manufacturing planned to mitigate geopolitical risks and ensure regulatory compliance, and the inclusion of Fast Track designations from the FDA for both IBI363 in NSCLC and IBI343 in pancreatic cancer underscores the therapeutic potential and accelerates development timelines, yet these de-risking factors and near-term catalysts like upcoming Phase III data readouts for zasocitinib in psoriasis and rusfertide in polycythemia vera are not being sufficiently weighted in current valuations despite their proximity to commercialization.
The company's operational efficiency program is delivering sustainable cost discipline that is underappreciated by investors, as evidenced by the JPY 27.4 billion in restructuring costs recognized in H1 FY25 from eliminating 600 positions and optimizing real estate, which is directly reducing R&D and SG&A expenses and creating structural OpEx savings that will persist beyond the near term; this efficiency drive, combined with the shift toward in silico drug discovery enabled by the Nabla Biosciences partnership—where over 90% of research programs are expected to be AI-enabled by next year—is enhancing R&D productivity and accelerating molecule progression without proportional cost increases, allowing Takeda to maintain investment in high-potential pipelines like mezagitamab for IgA nephropathy, which demonstrated stable eGFR at 96 weeks post-dose in proof-of-concept data, suggesting disease-modifying potential and durability of response that could redefine treatment paradigms in a large, underserved market, yet the market remains focused on near-term FX headwinds and VYVANSE LOE impacts rather than recognizing these efficiency gains as permanent margin expansion levers.
Despite the revision of ENTYVIO's full-year growth forecast to 6% at CER due to competition and slower Pen conversion, the underlying trajectory of the product remains robust, with U.S. Pen volume growing 20% sequentially and now representing 9% of U.S. sales, indicating early but accelerating adoption of a higher-margin, patient-preferred delivery mechanism that is expected to gain formulary traction and drive long-term growth as access barriers are resolved; concurrently, the subcutaneous immunoglobulin portfolio continues to deliver double-digit growth, albumin is poised for high single-digit growth in H2 FY25 based on accelerated demand outside China and secured sustainable tenders, and PDT as a whole remains on track for mid-single-digit annual growth, demonstrating that the diversification away from VYVANSE-dependent revenue is progressing successfully and that the launch and growth portfolio—now over 50% of total revenue—is poised to accelerate in H2 as generic erosion moderates, a dynamic the market is overlooking in favor of short-term volatility.

Takeda's strategic partnership with Innovent Biologics represents a transformative catalyst that the market is underestimating, as it adds three differentiated oncology assets with global rights outside Greater China and an initial addressable market exceeding $48 billion, positioning the company to become a leader in solid tumor treatment where it previously had minimal presence; the collaboration leverages cost-sharing arrangements like the 60-40 split for IBI363 and Blackstone partnership for mezagitamab to manage R&D expenses while advancing late-stage pipeline candidates, with U.S.-based manufacturing planned to mitigate geopolitical risks and ensure regulatory compliance, and the inclusion of Fast Track designations from the FDA for both IBI363 in NSCLC and IBI343 in pancreatic cancer underscores the therapeutic potential and accelerates development timelines, yet these de-risking factors and near-term catalysts like upcoming Phase III data readouts for zasocitinib in psoriasis and rusfertide in polycythemia vera are not being sufficiently weighted in current valuations despite their proximity to commercialization.
The company's operational efficiency program is delivering sustainable cost discipline that is underappreciated by investors, as evidenced by the JPY 27.4 billion in restructuring costs recognized in H1 FY25 from eliminating 600 positions and optimizing real estate, which is directly reducing R&D and SG&A expenses and creating structural OpEx savings that will persist beyond the near term; this efficiency drive, combined with the shift toward in silico drug discovery enabled by the Nabla Biosciences partnership—where over 90% of research programs are expected to be AI-enabled by next year—is enhancing R&D productivity and accelerating molecule progression without proportional cost increases, allowing Takeda to maintain investment in high-potential pipelines like mezagitamab for IgA nephropathy, which demonstrated stable eGFR at 96 weeks post-dose in proof-of-concept data, suggesting disease-modifying potential and durability of response that could redefine treatment paradigms in a large, underserved market, yet the market remains focused on near-term FX headwinds and VYVANSE LOE impacts rather than recognizing these efficiency gains as permanent margin expansion levers.
Despite the revision of ENTYVIO's full-year growth forecast to 6% at CER due to competition and slower Pen conversion, the underlying trajectory of the product remains robust, with U.S. Pen volume growing 20% sequentially and now representing 9% of U.S. sales, indicating early but accelerating adoption of a higher-margin, patient-preferred delivery mechanism that is expected to gain formulary traction and drive long-term growth as access barriers are resolved; concurrently, the subcutaneous immunoglobulin portfolio continues to deliver double-digit growth, albumin is poised for high single-digit growth in H2 FY25 based on accelerated demand outside China and secured sustainable tenders, and PDT as a whole remains on track for mid-single-digit annual growth, demonstrating that the diversification away from VYVANSE-dependent revenue is progressing successfully and that the launch and growth portfolio—now over 50% of total revenue—is poised to accelerate in H2 as generic erosion moderates, a dynamic the market is overlooking in favor of short-term volatility.

▼ Bear case

Takeda's guidance revision to a low single-digit percentage decline in core operating profit and core EPS, driven largely by transactional foreign exchange headwinds from euro volatility, reveals a structural vulnerability in its cost base that the market may be underpricing, given the company's significant manufacturing footprint in Europe exposes it to persistent currency fluctuations that are not easily mitigated through operational adjustments alone, especially as the gross margin guidance was cut from 66% to 64.7% with half attributed to transactional FX and the other half to unfavorable product mix from declining VYVANSE and ENTYVIO revenues, suggesting that even with OpEx discipline, external macroeconomic forces could continue to pressure profitability beyond FY25, and while management cites long-term footprint rebalancing as a potential solution, this is a multi-year strategic shift that offers no near-term relief, leaving the company exposed to ongoing FX-driven earnings volatility that could undermine investor confidence in its ability to deliver consistent profit growth.
The cell therapy discontinuation, which resulted in a JPY 58.2 billion impairment and contributed significantly to the 27.7% decline in reported operating profit, highlights a deeper issue with Takeda's R&D risk assessment and capital allocation, as the decision to abandon this effort late in development suggests either flawed preclinical validation or an inability to navigate complex clinical and manufacturing challenges in a high-cost, high-failure-rate sector, raising concerns about the rigor of its pipeline prioritization process and whether similar misallocations could occur in other ambitious but unproven areas such as the Innovent-bispecific ADC IBI3001 or the orexin 2 receptor agonist oveporexton, especially given that the company is simultaneously advancing multiple high-investment modalities like ADCs and bispecifics without clear near-term revenue offsets, and the fact that this impairment was non-tax-deductible further amplified its impact on net profit and EPS, indicating that past strategic bets in innovative but unvalidated spaces have materially damaged shareholder value without delivering compensatory upside.
Although ENTYVIO remains the market share leader in IBD, the reduction in its full-year growth forecast from 9% to 6% at CER due to intensified competition, delayed Pen conversion, increased 340B population, and Medicare Part D impacts signals a maturation of the franchise that could limit its long-term upside potential, particularly as the Pen—despite 20% quarter-over-quarter growth in the U.S.—still constitutes only 9% of U.S. sales, suggesting slow adoption of a higher-margin formulation that may never achieve sufficient scale to offset pricing and channel pressures, and while the subcutaneous immunoglobulin portfolio shows double-digit growth, the broader IG segment is growing at only 3.1% due to Medicare Part D redesign impacts, albumin faces phasing and cost containment issues in China, and PDT growth remains modest at mid-single digits, collectively indicating that the legacy PDT and immunology businesses are unable to generate the high-growth, high-margin contribution needed to offset LOE-driven declines, leaving Takeda overly dependent on early-stage oncology and neuroscience pipeline candidates like zasocitinib, rusfertide, and oveporexton, whose commercial success is uncertain and years away, creating a near- to mid-term growth gap that the market may not be fully appreciating amid optimism over pipeline breadth.

Takeda's guidance revision to a low single-digit percentage decline in core operating profit and core EPS, driven largely by transactional foreign exchange headwinds from euro volatility, reveals a structural vulnerability in its cost base that the market may be underpricing, given the company's significant manufacturing footprint in Europe exposes it to persistent currency fluctuations that are not easily mitigated through operational adjustments alone, especially as the gross margin guidance was cut from 66% to 64.7% with half attributed to transactional FX and the other half to unfavorable product mix from declining VYVANSE and ENTYVIO revenues, suggesting that even with OpEx discipline, external macroeconomic forces could continue to pressure profitability beyond FY25, and while management cites long-term footprint rebalancing as a potential solution, this is a multi-year strategic shift that offers no near-term relief, leaving the company exposed to ongoing FX-driven earnings volatility that could undermine investor confidence in its ability to deliver consistent profit growth.
The cell therapy discontinuation, which resulted in a JPY 58.2 billion impairment and contributed significantly to the 27.7% decline in reported operating profit, highlights a deeper issue with Takeda's R&D risk assessment and capital allocation, as the decision to abandon this effort late in development suggests either flawed preclinical validation or an inability to navigate complex clinical and manufacturing challenges in a high-cost, high-failure-rate sector, raising concerns about the rigor of its pipeline prioritization process and whether similar misallocations could occur in other ambitious but unproven areas such as the Innovent-bispecific ADC IBI3001 or the orexin 2 receptor agonist oveporexton, especially given that the company is simultaneously advancing multiple high-investment modalities like ADCs and bispecifics without clear near-term revenue offsets, and the fact that this impairment was non-tax-deductible further amplified its impact on net profit and EPS, indicating that past strategic bets in innovative but unvalidated spaces have materially damaged shareholder value without delivering compensatory upside.
Although ENTYVIO remains the market share leader in IBD, the reduction in its full-year growth forecast from 9% to 6% at CER due to intensified competition, delayed Pen conversion, increased 340B population, and Medicare Part D impacts signals a maturation of the franchise that could limit its long-term upside potential, particularly as the Pen—despite 20% quarter-over-quarter growth in the U.S.—still constitutes only 9% of U.S. sales, suggesting slow adoption of a higher-margin formulation that may never achieve sufficient scale to offset pricing and channel pressures, and while the subcutaneous immunoglobulin portfolio shows double-digit growth, the broader IG segment is growing at only 3.1% due to Medicare Part D redesign impacts, albumin faces phasing and cost containment issues in China, and PDT growth remains modest at mid-single digits, collectively indicating that the legacy PDT and immunology businesses are unable to generate the high-growth, high-margin contribution needed to offset LOE-driven declines, leaving Takeda overly dependent on early-stage oncology and neuroscience pipeline candidates like zasocitinib, rusfertide, and oveporexton, whose commercial success is uncertain and years away, creating a near- to mid-term growth gap that the market may not be fully appreciating amid optimism over pipeline breadth.

Peer Comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HLN	Haleon plc	88.07 Bn	103.29	6.00	11.45 Bn
2	TEVA	Teva Pharmaceutical Industries Ltd	35.75 Bn	23.02	2.06	16.63 Bn
3	ZTS	Zoetis Inc.	31.84 Bn	12.05	3.35	9.05 Bn
4	TAK	Takeda Pharmaceutical Co Ltd	27.18 Bn	-10.29	0.59	28.76 Bn
5	UTHR	UNITED THERAPEUTICS Corp	23.09 Bn	17.93	7.28	-
6	RDHL	RedHill Biopharma Ltd.	21.32 Bn	2,931.66	2.24	-
7	VTRS	Viatris Inc	19.96 Bn	-67.32	1.37	14.34 Bn
8	NBIX	Neurocrine Biosciences Inc	17.66 Bn	26.41	5.69	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password